

MMO-4020(94)00805- 1

Syntheses of 3-Phenyl Substituted Indolizidin-2-ones and a Pyrrolizidin-2-one on the Route to Constrained Potential NKI Receptor Antagonists

Franca M. Cordero,^a Alberto Brandi, ^{a*} Simone Cristilli, ^a Francesco De Sarlo, ^a Giovanni Viti^b

a) Dipartimento di Chimica Organica "U. Schiff" and Centro CNR dei Composti Eterociclici, Università di Firenze, Via G. Capponi 9, I-50121 Firenze (Italy)

b) Menarini Industrie Farmaceutiche Riunite S.r.l., Via Sette Santi 3, I-50131 Firenze (Italy)

Abstract: 5-Benzoyl substituted isoxazolidines 3a,b and 4a,b, obtained by 1,3-dipolar cycloadditions of pyrroline N-oxide and tetrahydropyridine N-oxide to phenyl vinyl ketone, undergo a rearrangement to 3-phenyl-2,5,6,7-tetrahydro-3H-pyrrolizin-2-one and 3-phenyl-2,3,5,6,7,8-hexahydroindolizin-2one, catalysed by Al₂O₃, followed by a Michael addition to a second molecule of phenyl vinyl ketone. Isoxazolidines 3a,b, in presence of an excess of phenyl vinyl ketone, undergoes another rearrangement to a 6,7-dibenzoylindolizidin-7-ol (21) by a non-reductive isoxazolidine ring cleavage. Isoxazolidines 4a,b do not undergo this second rearrangement, but give the expected 3-phenyl-indolizidin-2-one (2), as a single diastereoisomer, by reductive N-O bond cleavage with Mo(CO)₆. The reaction mechanism for the new rearrangements are discussed.

In the last years several non-peptidic $NK₁$ receptor antagonists¹ have been extensively studied **for their potential usefulness in many pathological conditions. CP-963452 and CP-999943 are among the most potent NK1 receptor antagonists known up to day, and may represent the prototypes of a** class of structures containing aza-heterocyclic rings as the main skeleton.

Due to the widespread occurrence of pyrrolizidine and indolixidine skeletons throughout many families of biologically active compounds and our ongoing interest in the synthesis and application of N-bridgehead azaheterocycles,⁴ we envisioned structures of type A or B ($n = 1, 2$) as constrained analogues of both CP-96345 and CP-99994, which could represent, whether or not potent $NK₁$ receptor antagonists, powerful tools for the development of a pharmacophoric model.

We, therefore, planned the synthesis of compounds A and B in a racemic form starting from the 3-phenyl substituted pyrrolizidin-2-one $(n=1)$ 1 and indolizidin-2-one $(n=2)$ 2 which could be synthesized through the methodology, novel for this class of N-bridgehead compounds, described in the following retrosynthetic scheme (Scheme 1).⁵ It consists of a 1,3-dipolar cycloaddition of a cyclic (five or six membered) nitrone to phenyl vinyl ketone followed by a reductive cleavage of the N-O bond in the isoxaxolidines 3 (or 4) and au *in situ* intramolecular condensation of the resulting ketoamine. The only one close precedent of this methodology, to the best of our knowledge, was found in a synthesis of 3-hydroxy proline by a japanese group.⁶

In contrast to the vast collection of the literature dealing with the 1,3-dipolar cycloadditions of nitrones with alkenes,⁷ no reports were available, to the best of our knowledge, on the cycloadditions to phenyl vinyl ketone, whereas methyl vinyl ketone has received broader interest.^{7,8} We have, then, studied briefly the cycloaddition of phenyl vinyl ketone (7) to cyclic nitrones 5, 6, 8 and 9.

Phenyl vinyl ketone (7), easily available from the corresponding Mannich base, 9 reacted with the nitrones readily at room temperature affording rather complex mixtures of regioisomeric compounds (Table 1). The formation of 4-regioisomers (isoxazolidine numberings) is expected by FMO consideration, because of the strong electron-withdrawing character of the benzovl group.¹⁰ However, Tufariello in the cycloaddition of the nitrone 9 with methyl vinyl ketone obtained regioselectively a 5-acetyl isoxazolidine.⁸ Each regioisomer was also present as a pair of diastereoisomers, deriving from an exo or endo approach of the reactants, but the exo/endo ratio was detectable from the 1H NMR of the crude reaction mixture only for the 5-regioisomeric compounds and only tentatively assigned on the basis of the observation of the coupling pattern of the H5 (isoxazolidine numberings) resonance in the ¹H NMR spectrum (Table 1) in agreement with similar assignments made in the literature. 11 For example, in adduct **3a,b, the exe** product **3a** shows a triplet at δ 5.23 ppm (J=7.8 Hz) for the H5 (isoxazolidine numberings), whereas the *endo* product 3b shows a doublet of doublet at δ 5.20 ppm (J=8.0, 5.6 Hz). The same applies for adducts $10a$, b and $11a$, b, whereas both 5-regioisomeric (isoxazolidine numberings) adducts **4a**,b show doublet of doublets. In this case the assignment of the exo stereochemistry to the major compound has been made by analogy. A better structure elucidation needed a careful separation of the isomers. But the separation and purification of the complex cycloaddition mixtures proved to be impracticable, by column chromatography, due to the very low stability shown by the adducts on silica gel, particularly of those from the five-membered nitrones. In all cases, enriched mixtures of the stereoisomers in lower amomt and besides other rearrangement products were obtained.

TABLE 1

The observation of the low stability of the benzoyl isoxazolidines, particularly on treatment on silica gel, attracted our interest and prompted us to study various conditions to steer efficaciously the reactivity of the compounds. It was found that treatment of the isoxazolidines with an excess of phenyl vinyl ketone in the presence of neutral Ahunina (Type I) gave the dehydro-pyrrolizidinone 12

and indolixidinone **13** (Scheme **2).** For synthetic purpose, it was found practical to run the cycloaddition of the nitrone with an excess of the phenyl vinyl ketone $(4 \div 5 \text{ eq.})$ to obtain overall yields of 60% and 50% for **12** and **13,** respectively. Isoxazolidines **10** and **11** gave only decomposition products in the same conditions.

The structural assignment was based on the analysis of ¹H and ¹³C NMR spectra. The enaminone mojety is evidenced by the presence of a singlet for the proton (at δ 5.10 ppm for 12 and δ 5.02 ppm for 13) and appropriate resonances for C1 and C2 carbon atoms (δ 90.8 and 198.8 ppm for 12 and 6 95.7 and 199.1 ppm for 13, respectively). The phenyl group resonances are also highly diagnostic for the assignment of the structure, showing two different phenyl groups, only one vicinal to a carbonyl. The data confirm the structures shown as products of the rearrangement of the 5-benzoyl isoxazolidine ring followed by a Michael addition to a second molecule of phenyl vinyl ketone, rearrangement unprecedented to the best of our knowledge. The only close precedent is the thermal rearrangement of exe-methylene isoxazolidines to pyrrolidinones discovered by Uccella and co-workers¹² and later reinvestigated by Tufariello and Padwa. ¹³ In the present case, however, the dehydropyrrolidinones are formed at room temperature by simple catalysis of alumina.

On this ground the mechanism shown in Scheme 3 can be proposed. The role of the alumina (or silica gel) could be to favour the enolisation of the ketone. The exo -methylene form 14 undergoes an isoxazolidine-pyrrolidine rearrangement to give the ketone 15 in equilibrium with the enol 16 (Scheme 3). Elimination of H₂O from this intermediate gives the hydroxy-pyrrole derivative 17 which is in equilibrium with the enaminone 18. Finally 17 undergoes a Michael addition to a second molecule of phenyl vinyl ketone to give 12 or 13. A similar reactivity of 3-hydroxy-pyrroles, like 17,

has been recently documented by Wasserman. 14

The role of alumina (or silica gel) on the rearrangement suggests, however, a second mechanism for the formation of the ketol 15. The coordination of a Lewis acid or a proton to the nitrogen is able to open the isoxazolidine ring *via* the transfer of the acidic proton α to the benzoyl group as shown in Scheme 4. The resulting diketone 20, condenses to give the same ketol 15 of Scheme 3.

As a confirmation of the mechanisms proposed, the intermediate 18 $(n = 1)$ derived from the isoxazolidines 3, could be also observed *via* lH-NMR (characteristic synglets at 6 4.99 and 4.5 1 ppm for the Hl and H3 protons, respectively), although attempt of isolation failed for its very low stability. Moreover, the methyl substituted isoxazolidmes 10 in the same conditions (alumina, excess phenyl vinyl ketone, methylenechloride) uuderwent complete decomposition. These compounds, having a bridgehead methyl, cannot give the intermediate 17 (or 18). However, from these data, a conclusion cannot be drawn on which of the two mechanism proposed is more likely. **10**

The pyrroleisoxaxolidines 3, as aheady pointed out, resulted rather unstable and reactive. In fact, in the presence of an excess of phenyl vinyl ketone, they undergo another unexpected transformation.

Upon treatment of the pyrroleisoxazolidines 3 with phenyl vinyl ketone 7 (one equivalent in benzene at room temperature, without alumina!) the indolizidine 21 was isolated in good yield (60%). It was also found that, on nmning the cycloaddition with an excess of 7 for a prolonged time, 21 was the only compound isolated. Structure assignment has been made on the basis of NMR experiment (¹H and ¹³C) including COSY and HETCOR. The signal of H6 (dd at δ 4.49 ppm, J=11.8; 3.8 Hz) bonded with C6 (δ 48.0 ppm), the presence of two carbonyl resonances (δ 205.7 and 202.7 ppm) and the quaternary C7 resonance (6 81.9 ppm) are highly diagnostic for the structure assignment. Moreover, the IR spectrum shows an absorption at 3414 cm^{-1} , typical of O-H stretching.

The formation of 21 seems to originate from a mechanism analogous to that shown in Scheme 4. An initial Michael addition of the isoxazolidine nitrogen to 7 should afford the isoxazolidinium enolate intermediate 22 which is able to abstract (intramolecularly or intermolecularly) the acidic proton α to benzoyl group to afford the triketone 23 with ring opening. Triketone 23 undergoes ring closure by an intramolecular aldol condensation (Scheme 5).

An analogy to this mechanism can be found in the non-reductive opening of isoxazolidinium salt caused by bases.15 In our case the added base is not necessary because of the *in situ* formation of a strong enolate base, and the reaction does not require high temperature because of the intramolecular activation. However, the reaction is not of general applicability. Isoxazolidines **4a,b** don't give the analogous reaction, that is probably connected with the strain of a pyrroleisoxazoline structure, and methyl vinyl ketone, with isoxazolidines **3a,b,** leads to a complex reaction mixture.

Since the purification of cycloadducts by chromatography was inconvenient for a good chemical yield, the product of cycloadditions was used without purification for the synthesis of the target ketones 1 and 2. Our hypothesis envisioned the reduction of N-O bond followed by *in situ* condensation of the amino-ketone 24 formed (Scheme 6). To achieve the selective N-O bond reduction it was used $Mo(CO)_{6}$ in refluxing acetonitrile containing 10% water, a methodology recently reported for the reductive cleavage of isoxazolidines.¹⁶ In these conditions, the isoxazolidines **3a,b** failed to give the expected pyrrolizinone, affording only poor yield of unidentified products, whereas the isoxazolidines **4a,b** afforded a 45% yield (isolated, overall on two steps) of one single diastereoisomeric indolizidinone 2.

SCHEME 6

Also isoxazolidines **10** and **11, in the same** conditions, failed to give the relative ketones, and afforded only complex mixtures of products. Ni-Raney, tested as a reducing agent, did not provide any reduction product in these cases.

Ketone 2 shows a singlet at δ 3.46 ppm for H3 in the ¹H-NMR spectrum and a carbonyl (δ 212.2 ppm) and C3 (δ 76.3 ppm) resonances in the ¹³C-NMR, diagnostic for the assignment. The frans-{HSa-Ph) relationship has been assigned on the basis of the observation of characteristic strong absorptions, at 2791 and 2756 cm⁻¹ in the IR spectrum, known as Bohlmann's bands, ¹⁷ and associated with the number of axial protons antiperiplanar with the nitrogen lone pair in these Nbridgehead compounds.¹⁸ The observation of these bands is diagnostic for a *trans*-fusion of the two rings in 2 and for the *trans*-{H8a-Ph}. The formation of a single diastereoisomer is explained by the formation of 2 as the most thermodinamically stable isomer in the equilibrium with the enol form 26 (Scheme 6).

The isolation of the ketone 2 realizes the achievement of our goal, consisting in the discovery of a new methodology for the synthesis of N-bridgehead bicyclic ketones. Unfortunately this process is limited, as yet, to the obtainment of indolizidinones. For the synthesis of our target $NK₁$ receptor antagonists, a direct consequence resulted in the possibility of producing, at this stage, only molecules of type **B.**

The cis-substituted mdolizidinamine 29 has been synthesized in two steps (46% yield) by condensation of the ketone 2 with o -methoxybenzylamine (27) followed by reduction with NaBH 4 . The reduction is highly stereoselective, affording only the product deriving from the attack of the hydride *anti* to the phenyl group (Scheme 7). To obtain the *trans* isomer 35 an inversion of the stereochemistry at C2 was required. This was achieved by a Mitsunobu reaction.¹⁹ The ketone 2 was reduced to a mixture of isomeric *cis* and trans (3.7:1) alcohols 30 by NaBH₄. The major *cis*-alcohol 30 treated with DEAD, PPh₃ and phthalimide gave the phthalimidoylindolizidine 31 in 65% yield. The trans-substituted indolizidine 31 afforded the amine 32 by treatment with hydrazine hydrate. The amine 32 gave, by condensation with o -methoxybenzaldehyde (33), the imine 34 which was reduced *in situ with NaBH₄* to give the *trans*-substituted indolizidinamine 35 with a 57% yield on three steps (Scheme 8).

Compounds 29 and 35 were active as $NK₁$ receptor antagonists only at micromolar level in functional tests, but further studies are in progress to make use of these results for the design of more potent analogues.

EXPERIMENTAL SECTION

All the reaction were run under nitrogen atmosphere using anhydrous solvents. Melting points (m.p.) were measured with an RCH Kofler apparatus. ${}^{1}H$ and ${}^{13}C$ -NMR (CDCl3) spectra were recorded on a Varian Gemini (¹H 200 MHz); notation s, d, t, q, m e br indicate singlet, doublet, triplet, quartet, multiplet and broad, respectively. IR spectra were recorded in CDCl3 with a Perkin-Elmer 881 spectrofotometer. Mass spectra (MS) were recordeds on 5792A Hewlett-Packard and QMD 1000 Carlo Erba instruments. Microanalyses were measured with a Perkin-Elmer 240 C instrument. Phenyl vinyl ketone (7) was synthesized according to ref. 9. Nitrones 5,6 and 9 were synthesised according to general procedure from the corresponding amines (see ref. 7). Nitrone 8 was synthesised according to ref. 20.

Cycloaddition of nitrones to phenyl vinyl ketone (7)

A 1 M solution of 1 equivalent of the nitrone and 1 equivalent of phenyl vinyl ketone (7) is stirred at room temperature for the appropriate time (see Table 1). The reaction mixture is concentrated and quickly chromatographed on a short pad of silica gel to give compounds as mixtures of cycloadducts on ¹H-NMR monitoring. Further separation by flash column chromatography gives enriched fractions of the isomers.

em-3a: lH-NMR: 6 8.12-7.90 (m, 2H), 7.65-7.40 (m, 3H), 5.23 (t, J=7.8 Hz, lH), 4.13-3.98 (m, 1H), 3.87-3.70 (m, 1H), 3.51-2.70 (m, 2H), 2.46 (ddd, J=12.0; 7.5; 4.5 Hz, 1H), 2.15-1.60 (m, 4H); 13GNMR: 6 195.7 s, 135.3 s, 133.5 s, 129.1 d (2C), 128.5 d (2C), 79.8 d, 66.0 d, 56.5 t, 38.7 t, 30.7 t, 23.6 t; MS: m/z (relative intensity) 217 (M*, 25), 200 (24), 161 (50), 124 (34), 105 (IOO), 84 (63), 77 (100). endo-3b: ¹H-NMR: 8 8.12-7.98 (m, 2H), 7.61-7.31 (m, 3H), 5.20 (dd, J=8.0; 5.6 Hz, lH), 3.82-3.65 (m, lH), 3.45-3.29 (m, lH), 3.09-2.95 (m, lH), 2.94 (ddd, J=12.4; 7.8; 5.6 Hz, lH), 2.28 (ddd, J=12.4; 8.0; 3.5 Hz, lH), 2.15-1.86 (m, 2H), 1.84-1.54 (m, 2H). 13C-NMR: 6 197.5 s, 134.8 s, 133.1 d, 129.1 d (2C), 128.3 d (2C), 78.8 d, 65.3 d, 57.0 t, 38.7 t, 31.2 t, 24.0 t.

em-4a: lH-NMR: 6 8.12-7.99 (m, 2H), 7.66-7.40 (m, 3H), 5.28 (dd, J=9.3;3.8 Hz, lH), 3.59- 3.43 (m, lH), 2.70-2.49 (m, 2H), 2.32-2.18 (m, IH), 2.08-1.12 (m, 7H); 13C-NMR: 6 195.4 s, 135.0 s, 133.4 d, 128.9 d (2C), 128.5 d (2C), 76.8 d, 65.9 d, 55.1 t, 32.7 t, 29.1 t, 24.7 t, 23.5 t; IR: 3069, 2948, 1690, 1598, 1448, 1223 cm⁻¹, MS; m/z (relative intensity) 231 (M⁺⁺, 29), 214 (45), 200 (13), 126 (100), 105 (100), 98 (65), 84 (81), 77 (100). endo-4b:¹H-NMR: δ (the only discerned signal) 5.44 (dd, J=9.7; 4.5 Hz, 1H); 13 C-NMR: δ (the only discerned signals) 78.1 d, 59.5 d, 50.4 t, 33.5 t.

exo-10a: ¹H-NMR: δ 8.12-7.99 (m, 2H), 7.68-7.39 (m, 3H), 5.27 (t, A part of an AXY system, J=8.0 Hz, 1H), 3.41-3.21 (m, 1H), 3.18-2.99 (m, 1H), 2.63 (X part of an AXY system, J=12.4; 8.0 Hz, 1H), 2.41 (Y part of an AXY system, J=12.4; 8.0 Hz, 1H), 2.25-1.65 (m, 4H), 1.32 (s, 3H); ¹³C-NMR: 6 195.9 s, 135.3 s, 133.4 d, 129.1 d (2C), 128.5 d (2C), 79.3 d, 72.5 s, 55.4 t, 44.6 t, 36.6 t, 26.0 q, 23.4 t. MS: m/z (relative intensity) 231 (M⁺⁺, 18), 216 (10), 202 (2), 188 (4), 126 (19), 105 (100), 98 (65), 77(100). endo-10b: ¹H-NMR: δ 8.12-8.04 (m, 2H), 7.62-7.39 (m, 3H), 5.23 (dd, A part of an AXY system, J=8.2; 6.6 Hz, 1H), 3.50-3.32 (m, 1H), 3.25-3.05 (m, 1H), 2.71 (X part of an AXY system, J=12.4; 6.6 Hz, lH), 2.55 (Y part of an AXY system, J=12.4; 8.2 Hz, IH), 2.20-1.70 (m, 4H), 1.25 (s, 3H); 13C-NMR: 6 197.7 s, 134.9 s, 133.1 d, 129.2 d (2C), 128.4 d (2C), 78.8 d, 72.5 s, 55.6 t, 45.3 t, 37.4 t, 25.3 q, 24.2 t; MS: m/z (relative intensity) 231 (M⁺⁺, 87), 216 (20), 202 (17), 188 (78), 126 (8), 105 (loo), 98 (14), 77 (38).

exo-11a: ¹H-NMR: δ 8.09-7.99 (m, 2H), 7.73-7.42 (m, 4H), 7.19-7.05 (m, 3H), 5.43 (t, J=8.5 Hz, 1H), 3.29-2.75 (m, 4H), 2.31-2.17 (m, 2H); 13 C-NMR: d 197.8 s, 135.9 s, 135.0 s, 133.2 s (aromatic carbons not assigned), 81.4 d, 64.2 d, 49.8 t, 39.3 t, 30.2 t; IR: 3069, 3027, 2958, 2928, 2856, 1687, 1597, 1448, 1276, 1250, 1227 cm-l; MS: m/z (relative intensity) 279 (M+, 14), 248 (4), 147 (64), 130 (27), 129 (40), 115 (19), 105 (lOO), 91 (15), 77 (100). endo-lla: lH-NMR: 8 8.12-8.06 (m, 2H), 7.59-7.39 (m,4H), 7.28-7.11 (m, 3H), 5.47 (dd, J=9.4;4.0 Hz, IH), 4.63 (t, J=8.7 Hz, H-I), 3.35.2.12 (m, 6H); ¹³C-NMR; δ 196.2 s, 136.4 s, 135.1 s, 132.9 s (aromatic carbons not assigned), 78.8 d, 62.2 d, 48.5 t, 38.4 t, 29.6 t; IR: 3069,3027,2929,2854, 1677, 1597, 1447, 1277, 1222 cm-l; MS: m/z (relative intensity) 279 (M*, 8), 248 (26), 174 (63), 159 (51), 148 (41), 147(100), 130 (90). 115 (82), 105 (100), 91 (46), 77 (100). 4-Benzoyl regioisomer (isoxazolidine numbering): $1H\text{-NMR}$: 8 7.92-7.87 (m, 2H), 7.63-7.39 (m, 4H), 7.26-6.98 (m, 3H), 5.23 (d, J=7.7 Hz, HI), 4.65 (dd, J=lO.l; 7.9 Hz, lH), 4.41 (ddd, J=lO.l; 6.5; 7.7 Hz, lH), 4.02 (dd, J=7.9; 6.5 Hz, lH), 3.40-2.85 (m, 4H); 13C-NMR: 6 198.7 s, 137.3 s, 135.1 s, 133.4 s (aromatic carbons not assigned), 70.7 t, 65.9 d, 58.0 d, 48.7 t, 28.7 t; IR: 3067, 3029, 2928, 2856, 1680, 1596, 1447, 1360, 1278, 1234 cm-l; MS: m/z (relative intensity) 279 (M*, 7), 248 (lOO), 174 (9), 148 (38), 147 (lOO), 130 (61), 105 (lOO), 91 (57), 77 (100).

@nthesis of 3(3'-phenyl-3%xo)propyl-3-phenyl-2,5,4, I-tetralrydro-3H-pyrrolirin-2-one (12).

To a solution of pyrroline-N-oxide (5) (340 mg, 4 mmol) in methykne chloride (3 mL) was added slowly a solution of 1.247 g (9.4 mmol) of 7 in 6 mL of methylene chloride, and 5 g of neutral ahunina (Type I). After 12 h at room temperature, the mixture was filtered, concentrated, and the oily residue was flash chromatographed (eluent ethyl acetate-petroleum ether 1:l) to give 789 mg of 12 (60% yield).

12: Rf=0.17 (eluent ethyl acetate-petroleum ether 1:1); 1 H-NMR: 8 7.96-7.91 (m, 2H), 7.60-7.22 (m. 8H), 5.10 (s, HI.), 3.36 (ddd, J=9.5; 8.4; 4.8 Hx, lH), 3.17 (ddd, J=9.5; 8.1; 6.6 Hz, lH), 2.92-2.83 (m, 2H), 2.79-2.51 (m,4H), 2.32-1.97 (m, 2H); 13C-NMR: 6 203.4 s, 198.8 s, 183.4 s, 136.2 s (2C), 133.0 d, 128.6 d (2C), 128.4 d (2C), 127.8 d (2C), 127.7 d, 125.8 d (2C), 90.8 d, 72.8 s, 44.2 t, 3 1.9 t, 27.7 t, 27.1 t, 22.8 t; JR: 3065,2934,2877, 1708, 1679, 1648, 1598, 1529, 1448, 1304 cm⁻¹; MS: m/z (relative intensity) 331 (M⁺⁺, 50), 302 (10), 226 (20), 222 (46), 212 (100), 198 (100), 184 (13), 182 (14), 170 (18), 115 (23), 110 (17), 105 (46), 91 (22), 77 (100); Anal. Calcd for C22H2lN02: C, 79.73; H, 6.39; N, 4.23. Found: C, 79.45; H, 6.70; N, 4.05.

Synthesis of 3(3'-phenyl-3'-oxo)propyl-3-phenyl-2,3,5,6, 7,8-haahydroindolizin-2-one (13)

To a solution of 3,4,5,6-tetrahydropyridine-N-oxide (6) (547 mg, 5.5 mmol) in methylene chloride (10 mL) was added slowly a solution of 2.181 g (16.5 mmol) of 7 in 6 mL of methylene chloride, and 8 g of neutral alumina (Type I). After 14 h at room temperature, the mixture was filtered, concentrated, and the oily residue was flash chromatographed (eluent ethyl acetate-petroleum ether 3: 1, then methanol). Concentration of the most polar fraction gave 955 mg of 13 (50% yield).

13: m.p. 95-96°C (diethyl ether). ¹H-NMR: d 7.97-7.94 (m, 2H), 7.59-7.53 (m, 1H), 7.48-7.42 (m, 2H), 7.37-7.24 (m, 5H), 5.02 (s, lH), 3.18-3.07 (m, lH), 3.05-3.58 (m, 6H), 2.55-2.40 (m,lH), 1.88-1.61 (m, 4H); 13C-NMR: d 200.3 s, 199.1 s, 177.4 s, 136.5 s (2C), 133.2 d, 128.9 d (2C), 128.6 d (2C), 128.2 d (2C), 128.0 d, 126.0 d (2C), 95.8 d, 75.1 s, 40.5 t, 31.9 t, 26.5 t, 25.4 t, 22.5 t, 19.2 t; JR: 3064, 2957, 2869, 1679, 1642, 1509, 1447, 1360, 1243 cm-l; MS: m/z (relative intensity) 345 **(M-+,40), 317 (3), 240 (3), 238 (3), 226 (19), 213 (loo), 212 (91), 198 (16), 184 (28), 156** (12), 115 (19), **105 (53), 77 (81); Anal. C&d for** C23H23N02: C,79.97; H, 6.71; N, 4.05. Found C, 79.98; H, 6.66; N, 4.17.

$Synthesis$ of 6,7-dibenzoyl-7-hydroxy-1, 2, 3, 5, 6, 7, 8, 8a-octahydroindolizine (21).

A solution of pyrroline-N-oxide (5) (1.2 g, 14 mmol) and phenyl vinyl ketone (7) (1.188 g, 9 mmol) in benzene (30 mL) was stirred at room temperature for 24 h. After concentration of the solution and flash chromatography (eluent petroleum ether-ethyl acetate 3:2) 961 mg of 21 ($R_f = 0.28$) (61%) was obtained as a solid.

21: m.p. = 110-111°C (ethanol); ¹H-NMR: δ 8.29-8.24 (m, 2H), 8.09-8.04 (m, 2H), 7.66-7.37 (m, 6H), 5.72 (d, J=2.6 Hz, lH, OH), 4.51 **(dd,** J=11.9; 3.8 Hz, H-I), 3.24 (dd, J=10.8; 3.8 Hz, H-J), 3.07 (td, J=8.3; 2.7 Hz, IH), 2.82-2.66 (m, HI), 2.61 (t, J=11.4 Hz, H-J), 2.45 (dd, J=13.4; *2.7 Hz,* **1I-Q** 2.28 **(q,** J=8.7 Hz, lH), 2.00-1.71 (m, 3H), 1.58-1.32 (m, 2H); 13C-NMR: 8 205.7 s, *202.7 s, 135.6 s, 134.5 s, 133.7 d, 132.6 d, 130.2* **d** (2C), 128.6 d (2C), 128.5 d (2C), 127.9 d (2C), 81.9 S, 57.8 d, 52.6 t, 50.4 t, 48.0 d, 40.5 t, 29.5 t, 21.3 t; JR: 3424 (br), 3030,2972, 1660, 1597, 1218 cm-l; MS: m/z (relative intensity) 349 (M⁺⁺, 13), 331 (2), 244 (81), 226 (9), 217 (52), 201 (68), 124 (11), 112 (11), 105 (100), 96 (26), 83 (18), 77 (74); Anal. Calcd for C₂₂H₂₃NO₃: C, 75.62; H, 6.63; N, 4.01. Found: C, 75.71; H, 6.80; N, 4.31.

Synthesis of 3-phenyl-1, 2, 3, 5, 6, 7, 8, 8a-octahydroindolizin-2-one (2).

A solution of nitrone 6 [obtained by oxydation of N-hydroxypiperidine (505 mg, 5 mmol) at O°C with yellow HgO (4.4 g, 20.4 mmol)] and phenyl vinyl ketone (7) (1.188 g, 7 mmol) in methylene chloride (10 mL), was stirred 48 h at room temperature. The solution was concentrated and the residue dissolved in acetonitrile (50 mL) and H₂O (1 mL). After addition of Mo(CO)₆ (924 mg, 3.5 mmol) the mixture was refluxed 4 h and concentrated. Flash chromatography (eluent petroleum ether-ethyl acetate 1O:l) gave 490 mg of 2 (45% yield of two steps). Using for the reaction the isolated isoxazolidines $3a,b$ (0.5 eq. di Mo(CO)₆; 15 eq. di H₂O) ketone 2, only slightly more pure, was obtained in 47% yield.

2: R $f=0.34$ (eluent petroleum ether-ethyl acetate 10:1), oil; ¹H-NMR: δ 7.39-7.29 (m, 5H), 3.46 (s, 1H), 2.93 (dm, J=11.4 Hz, 1H), 2.66-2.48 (m, 1H), 2.50 (dd, J=17.0; 5.3 Hz, 1H), 2.30-1.82 (m, 4H), 1.75-1.13 (m, 4H); 13C-NMR: 8 212.2 s, 136.4 s, 128.4 d (2C), 128.3 d (2C), 127.8 d, 76.3 d, 60.3 d, 51.1 t, 43.5 t, 31.2 t, 25.5 t, 24.6 t; IR: 3067, 3033, 2940, 2855, 2791 and 2756 (Bohlmann's bands), 1755, 1493, 1499, 1441, 1247, 1135 cm⁻¹; MS: m/z (relative intensity) 215 (M⁺⁺, 2), 214 (1), 186 (loo), 172 (13), 158 (9), 145 (15), 132 (21), 118 (16), 104 (43), 91 (18); Anal. Calcd for Cl4Hl7NO: C, 78.10; H, 7.96; N, 6.51. Found: C, 78.07; H8.09; N, 6.28.

Synthesis of cis-(2S^{*},3S^{*})-2-o-methoxybenzylamino-3-phenyl-1, 2, 3, 5, 6, 7, 8, 8a-octahydro*indblizine (29).*

A solution of ketone 2 (215 mg, 1 mmol), o-methoxybenzylamine (27, 274 mg, 2 mmol) and p-TsOH (catalytic) in benzene (4 mL) was heated at reflux for 3 h. After concentration, and elimination of the excess amine by kugel rohr distillation, the residue was dissolved in anhydrous EtOH (2.5 mL.) and cooled at 0°C. Sodium borohydride (67 mg, 1.7 mmol) was added in small portions and, after 2 h at O"C, the reaction mixture was left at room temperature for 12 h. After the usual work up, flash chromatography (eluent petroleum ether-ethyl acetate 1:1) gave 155 mg of 29 (46% yield).

29: $(Re = 0.30,$ eluent petroleum ether-ethyl acetate 1:1) ¹H-NMR: δ 7.36-7.20 (m, 5H), 7.16 (td, J=7.7; 1.9 Hz, 1H), 6.92 (dd, J=7.3; 1.9 Hz, 1H), 6.80 (tm, J=7.3 Hz, 1H), 6.74 (br d, J=8.1 Hz, H-J), 3.59 (s, 3H), 3.58 (d, J=l3.9 Hz, lH), 3.31 (d, J=7.3 Hz, H-J), 3.27 (d, J=13.9 Hz, lH), 3.15 (td, J=7.3; 5.7 Hz, 1H), 2.94-2.81 (m, 1H), 2.22 (ddd, J=11.8; 7.6; 6.1 Hz, 1H), 2.29-2.12 (m, 1H), 1.90-1.19 (m, 8H), 1.39 (td, J=11.1; 5.5 Hz, 1H); ¹³C-NMR; δ 157.5 s, 138.5 s, 129.6 d, 129.0 d (2C), 128.0 s, 127.9 d (2C), 127.8 d, 126.8 d, 120.0 d, 109.8 d, 74.0 d, 63.7 d, 57.2 d, 54.8 d, 51.7 t, 47.1 t, 39.2 t, 31.2 t, 25.4 t, 24.7 t; IR: 3026, 2935, 2859, 2790 and 2755 (Bohlmann's bands), 1605, 1495, 1465, 1240, 1120 cm-l; MS: m/z (relative intensity) 336 (M*, 3), 239 (5), 216 (4), 199(9), 172 (100), 144 (12), 121 (27), 104 (29), 91 (70); Anal. Calcd for C₂₂H₂₈N₂O: C, 78.53; H,8.39; N, 8.33. Found: C, 78.26; H, 8.79; N, 8.00.

Synthesis of cis-(2S*,3S*)- and *trans-(2R*,3S*)-2-hydroxy-3-phenyl-1, 2, 3, 5, 6, 7, 8, 8aoctahy&oindolizine (30).*

To a solution of ketone *2 (237* mg, 1.1 mmol) in anhydrous EtOH (2.5 mL), cooled at O"C, sodium borohydride (67 mg, 1.7 mmol) was added in small portions and, after *2* h at O'C, the reaction mixture was left at room temperature for 12 h. After the usual work up, concentration of the organic solution gave 230 mg (96%) of a pure mixture of the *cis* and *trans* alcohols 30 in 3.7:1 ratio. Major *cis* isomer can be separated in part by flash chromatography (eluent methylene chloride-methanol (added of 1% NH₄OH) 20:1).

cis-30: Rf= *0.38;* m. p.= *77-78 "C;* JH-NMR: 6 7.41-7.20 (m, 5H), 4.26-4.15 (m, IH), 3.25 (d, J=5.8 Hz, 1H), 2.92-2.84 (m, 1H), 2.44 (ddd, J=13.2; 7.6; 7.0 Hz, 1H), 2.10-1.95 (m, 1H), 1.91-1.19 (m, 9H); 13C-NMR: 6 137.0 s, 129.0 d (2C), 128.4 d (2C), 127.4 d, 75.5 d, 72.0 d, 63.4 d, 51.5 t, 40.6 t, 31.3 f 25.4 t, 24.7 t; JR: 3582, 3083, 3029, 2938, 2854, 2793, 1605, 1449, 1442, 1225, 1058 cm⁻¹; MS: m/z (relative intensity) 217 (M⁺⁺, 8), 173 (36), 172 (100), 140 (6), 96 (3), 91 (25), 84 (27), 77 (100); Anal. Calcd for C₁₄H₁₉NO: C, 77.38; H, 8.81; N, 6.45. Found: C, 77.35; H, 9.04; N, 6.05.

rrans-30: Rf= 0.32; 1H-NMR: 6 (the only discerned signals) *4.03* (ddd, J=7.9; 5.3; 2.9 Hz, lH), 3.05 (d, J=5.3 Hz, lH), 2.71 (dm, J=10.7 Hz, 1H).

Synthesis of trans-(2R*,3S*)-2-phtalimidoyl-3-phenyl-1, 2, 3, 5, 6, 7, 8, 8a-octahydroindolizine *(31).*

To a solution of alcohol *cis-30* (180 mg, 0.83 mmol), phthalimide (162 mg, 1.1 mmol) and PPh3 (298 **mg,** 1.1 mmol) in **anhydrous** THF *(5 mL),* DEAD (191 mg, 1.1 mmol) was added slowly and the reaction left at room temperature for 12 h. The solid obtained after concentration was washed with diethyl ether and the solid residue recrystallized from ethanol gave 188 mg of 31 (yield 65%).

31: m. p. = 179-180°C (ethanol); ¹H-NMR; δ 7.82-7.65 (m, 4H), 7.32-7.20 (m, 5H), 4.60 (ddd, J=11.6; 8.3; 4.4 Hz, 1H), 3.70 (d, J=8.3 Hz, 1H), 2.93-2.68 (m, 2H), 2.29-2.14 (m, 1H), 2.08-1.24 (m, 8H); 13C-NMR: 8 168.0 s (2C), 139.9 s, 133.8 d (2C), 131.8 s (2C), 128.4 d (2C), 127.6 d (3C), 123.1 d (2C), 71.7 d, 63.5 d, 55.6 d, 50.6 t, 34.5 t, 31.3 t, 25.4 t, 24.3 t; IR: 3005, 2938, 1708 (very strong), 1601, 1360, 1221cm⁻¹; MS: m/z (relative intensity) 346 (M⁺⁺, 5), 269 (3), 199 (100), 198 (77), 172 (74), 156 (18), 104 (35), 97 (31), 76 (18).

Synthesis of trans-(2R^{*},3S^{*})-2-o-methoxybenzylamino-3-phenyl-1, 2, 3, 5, 6, 7, 8, 8a-octahydro*indolizine (35).*

A solution of 31(139 mg, *0.4* mmol) and hydrazine hydrate (100 pL, *10.3 mg, 1* mmol) in ethanol *(8 mL) was* heated at refhrx for 15 h. After filtration on celite and concentration were obtained **102** mg of amine 32 pure enough to be utilized for the next reaction without purification. [32: 1 H-NMR: δ 7.40-7.18 (m, 5H), 3.22 (ddd, J=9.7; 6.6; 3.4 Hz, 1H), 2.90 (d, J=6.6 Hz, 1H), 2.90-2.60 (m, 2H), 2.69 (dm, J=11.0 Hz, 1H), 2.45-2.28 (m, 1H), 1.96 (dd, J=13.0; 10.0 Hz, 1H), 1.92-1.20 (m, 8H); 13C-NMR: 8 140.8 s, 128.3 d (2C), 127.7 d (2C), 127.3 d, 79.2 d, 62.8 d, 58.3 d, 50.6 t, 39.1 t, 31.1 t, 25.2 t, 24.2 t]. The amine 32 was dissolved in ethanol (1 mL) and to the solution added o anisaldehyde (33,68 mg, 0.5 mmol) and anhydrous sodium carbonate. After 3 h at room temperature, the reaction mixture was cooled at 0°C and sodium borohydride (24 mg, 0.6 mmol) added in small portions. After 24 h at room temperature the mixture was subjected to normal work up. FIash chromatography (eluent petroleum ether-ethyl acetate 3:2) gave 77 mg of 35 (overaIl yield 57%).

35: ¹H-NMR: δ 7.40-7.23 (m 5H), 7.17 (td, J=7.7; 1.8 Hz, 1H), 6.98 (dd, J=7.4; 1.8 Hz, 1H), 6.80 (tm, J=7.4 Hz, 1H), 6.76 (br d, J=7.7 Hz, 1H), 3.65 (s, 4H), 3.06-2.96 (m, 2H), 2.66 (m, 1H), 2.32 (m, 1H), 1.90-1.18 (m, 11H); ¹³C-NMR; δ 157.5 s, 142.1 s, 129.8 d, 128.2 d (2C), 128.1 d, 128.0 d (2C), 127.9 s, 127.1 d, 120.2 d, 110.0 d, 77.7 d, 64.1 d, 63.3 d, 54.9 q, 50.9 t, 48.1 t, 37.7 t, 31.3 f 25.4 f 24.4 t; IR: 3029, 2940, 2793 and 2757 (Bohhmum's bands), 1600, 1492, 1454, 1242 cm⁻¹; MS: m/z (relative intensity) 336 (M⁺⁺, 23), 239 (31), 199 (20), 198 (49), 172 (100), 121 (64), 90 (100), 77 (76); Anal. Calcd for C₂₂H₂₈N₂O: C, 78.53; H, 8.39; N, 8.33. Found: C, 78.64; H, 8.46; N, 8.18.

Acknowledgment. Authors thank M.U.R.S.T. (Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Rome-Italy) (IMI Grant n. 56665) for partial IinanciaI support and a fellowship for M. F. Cordero.

REFERENCES AND NOTES

- 1. Logan, M.E.; Goswami, R.; Tomczuk, B. E.; Venepalli, B. R. *Annual Reports in Medicinal Chemistv* **1990,43-5** 1.
- 2. a) Snider, R. M.; Constantine, J. W; Lowe, III, J. A.; Longo, K. P.; Lebel, W.S.; Woody, H.A.; Drozda, S. E.; Desai, M. C.; Viuick, F. J.; Spencer, RW.; Hess, H.-J. *Science,* 1991, 251, 435- 437; b) Lowe, III, J. A.; Drozda, S. E.; Snider, R M.; Longo, K. P.; Bordner, J. *Bioorg. Mea! Chem. Lert.,* 1991, I, 129-132; c) Lowe, J. A., III, Drugs *of thejimre* 1992, 17, 1115-1121; d) Rosen, T.; Seeger, T. F.; McLean, S.; Desai, M. C.; Guarino, K. J.; Biyce, D.; Pratt, K.; Heym, J. J. *Mea! Chem. 1993, 36,3197-3201.*
- 3. Desai, M. C.; Thadeio, P. F.; Lefkowitz, S. L. *Tetrahedron Lett.* 1993, 34, 5831-5834.
- **4.** a) Brandi, A.; Cordero, F. M.; De Sarlo, F.; Goti, A.; Guarna, A. *Synlett 1993, 1-8;* b) Cordero,

F. M.; Anichini, B.; Goti, A.; Brandi, A. *Tetrahedron* **1993,** *49, 9867-9876; c)* Brandi, A.; Cordero, F. M.; Goti, A.; Guama, A. *Tetrahedron Left.* **1992,** *33, 6697-6700;* d) Brandi, A.; Dürüst, Y.; Cordero, F. M.; De Sarlo, F. *J. Org. Chem.* 1992, 57, 5666-5670.

- *5. Preliminary* communication: Cordero, F. M.; Brandi, **A.; De Sarlo, F.; Viti, G. J. C. S.** *Chem.* Commun. 1994, 1047-1048.
- 6. Hara, J.; Inouye, Y.; Kakisawa, H. *Bull. Sot. Chim. Japan* 1981,54,3871.
- 7: a) Tufariello, J. J. in *1,3-Dipolar Cycloaddition Chemistry*; Padwa, A. Ed.; Wiley-Interscience: New York, 1984; Vol. 2, 83; b) Breuer, E. in *Nitrones, Nitronates and Nitroxides;* Patai, S.; Rappoport, Z. Eds.; Wiley: 1989; 139-244, and 245-312; c) Confalone, P. N.; Huie, E. M. Org. *Reac.* **1988,36,** *l-173;* **d)** Black, D. St.; Crazier, R F.; Davis, V. C. *Synthesis* **1975,205-221;** e) Torssell, K. B. G. Nitrile Oxides, Nitrones and Nitronates in Organic Synthesis; Feuer, H. Ed.; VCH Publishers: New York, 1988.
- 8. a) Tufariello, J. J.; Asrof Ali, Sk. *Tetrahedron Left.* **1978,4647-4650;** b) Andersen, S. H.; Das, **N.** B.; Jorgennsen, R. D.; Kjeldsen, G.; Knudsen, J. S.; Sharma, S. C.; Torssell, K. B. G. *Acta Chem. Scand* **1982,** *B* 36, 1-14.
- 9. a) Denis, G. I.; Stepanavichyus, Yu. Yu. Zh Org. *Kh* **1968, 4,** 1391-1393; *Engl. Ed* **1968, 4, 1340-1342; b)** Tramontini, M. *Synthesis* **1973,703-775.**
- 10. a) Sims, J.; Houk, K. N. J. *Am. Chem. Sot.* **1973,** 95, 5798-5800; a) Fleming, I. *Frontier Orbitals and Organic Chemical Reactions;* **Wiley: New York, 1976.**
- **11.** DeShong, P.; Dicken, C. M.; Staib,R. R.; Freyer, A. J.; Weinreb, S. M. J. Org. *Chem.* **1982,** 47, 43974403.
- 12. a) Aversa, M. C.; Cum, G.; Uccella, N. J. *Chem. Sot. Chem. Commun* 1971, 156-157; b) Cum, G.; Sindona, G.; Uccella, N. J. Chem. Soc. Perkin Trans. I 1976, 719-721. For a related reammgement in 2,1-benzoisoxazole compounds see: a) Camps, R *Arch Pharm.,* 1982, 240, 423; b) Bamberger, E.; Elger, F. Chem. Ber., 1903, 36, 1611-1625; c) Bruining, W. J. Rec. *Trav. Chim.,* **1922,41,655.**
- 13. (a) J. J. Tufariello, Sk. Asrof Ali and H. O. Klingele, *J. Org. Chem.*, 1979, 44, 4213-4215; (b) A. Padwa, M. Matzinger, Y. Tomioka and M. K. Venkatramanan, J. Org. Chem., 1988, 53, 955-963; (c)A. Padwa, D. N. Kline and B. H. Norman, J. Org. *Chem.,* **1989,54,810-817.**
- 14. (a) Wasserman, H. H.; Fukuyama, J.; Murugesan, N.;van Duzer, J.; Lombardo, L.; Rotello, V.; McCarthy, K. J. *Am. Chem. Sot.,* **1989, Ill,** 371-372; (b) Wasserman, H. H.; Cook, J. D.; Vu, C. B. *Tetrahedron Left.,* **1990,3Z,** *4945-4948.*
- **15.** a) Mumhashi, S. I.; Kodera, Y.; Hosomi, T. *Tetrahedron Left.* **1988,29,5949-5952;** b) Hootele, C.; Ibebeke-Bo_magwa, W.; Driessens, F.; Sabil S. *Bull. Sot. Chim. Belg.* **1987,96,** 57-61.
- 16. Cicchi, **S.; Goti, A.; Brandi, A.; Guama, A.; De Sarlo, F.** *Tetrahedron Left.* **1990,** 31, 3351- 3354.
- 17. Bohhnann, F. *Chem. Ber.* **1958,91,2157-2167.**
- 18. Crabb, T. A.; Newton, R. F.; Jackson, D. *Chem. Rev.* 1971, 71, 109-126.
- 19. Mitsunobu, 0. *Synthesis* **1981, l-28.**
- 20. Brandman, H. A.; Conley, R. T. J. Org. Chem. 1973, 38, 2236-2238.

(Received in UK 4 August 1994, revised 9 September 1994, accepted 16 September 1994)